Gastrointestinal damage induced by cytostatic treatment does not affect the bioavailability of co-trimoxazole

Chemotherapy

Volumn 45, Issue 6, 1999, Pages 399-404

  Nyhlen A ^a   Johnsson, A ^a   Hoglund, P ^a   Ljungberg, B ^a   Nilsson Ehle, I ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bioavailability; Co trimoxazole; Cytostatics; Gastrointestinal damage; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FOLINIC ACID; METHOTREXATE; PREDNISONE; SULFONAMIDE; VINCRISTINE;

ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DIGESTIVE SYSTEM INJURY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; GASTROINTESTINAL MUCOSA; HUMAN; LYMPHOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL AVAILABILITY; BLEOMYCIN; CYCLOPHOSPHAMIDE; DIGESTIVE SYSTEM; DOXORUBICIN; HUMANS; LEUCOVORIN; LYMPHOMA; METHOTREXATE; MIDDLE AGED; PREDNISONE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; VINCRISTINE;

EID: 0032737203     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007232     Document Type: Article

References (14)

1. Klimo P, Connors J: MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma. Ann Intern Med 1985;102:596.
2. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, WHO, 1979, vol 48, pp 17-18.
3. Siersback-Nielsen K, Mölholm Hansen J, Kampmann J, Kristensen M: Rapid evaluation of creatinine clearance. Lancet 1971;i:1133-1134.
4. 51Cr-EDTA as a measure of GFR. Scand J Clin Lab Invest 1981;41:611-616.
5. 4-acetylsulphamethoxazole in body fluids. J Chromatogr A 1983;278:337-345.
6. Beal S, Sheiner L: The NONMEN system. Am Stat 1980;34:118.
7. Beal S, Sheiner L: Estimating population kinetics. Crit Rev Biomed Eng 1982;8:195.
8. Johnson E, MacGowan A, Potter M, Stockley R, White L, Slade R, Reeves D: Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy. J Antimicrob Chemother 1990;25: 837-842.
9. Bach M, Gold O, Finland M: Absorption and urinary excretion of trimethoprim, sulphamethoxazole, and trimethoprim-sulphamethoxazole: Results with single doses in normal young adults and preliminary observations during therapy with trimethoprim-sulphamethoxazole. J Infect Dis 1973;128(suppl):S584-S598.
10. Kaplan S, Weinfeld R, Abruzzo C, McFaden K, Jack ML, Weissman L: Pharmacokinetic profile of trimethoprim-sulphamethoxazole in man. J Infect Dis 1973;128(suppl):S547-S555.
11. Rieder J, Schwartz D, Fernex M, Bergen T, Broadwall E, Blumberg A, Cottier P, Scheitlin W: Pharmacokinetics of the antibacterial combination sulphamethoxazole plus trimethoprim in patients with normal or impaired kidney function. Antibiot Chemother 1974;18:148-198.
12. Cockerill F III, Edson R: Trimethoprim-sulphamethoxazole. Mayo Clin Proc 1991;66:1260-1269.
13. Kahlmeter G, Olsson-Liljequist B: MIC values of wild type bacteria. The Swedish Reference Group of Antibiotics database on internet, 1997, www:ltkronoberg.se/ext/raf/ raf.htm.
14. Grunberg E: The effect of trimethoprim on the activity of sulfonamides and antibiotics in experimental infections. J Infect Dis 1973;128 (suppl):S478-S485.